Silver Rock Financial LP purchased a new stake in shares of Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU – Get Rating) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 46,243 shares of the company’s stock, valued at approximately $463,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in PBAXU. Sage Mountain Advisors LLC purchased a new stake in shares of Phoenix Biotech Acquisition during the 4th quarter valued at about $653,000. Wealthspring Capital LLC purchased a new stake in shares of Phoenix Biotech Acquisition during the 4th quarter valued at about $2,653,000. Robinson Capital Management LLC bought a new position in shares of Phoenix Biotech Acquisition in the 4th quarter worth approximately $61,000. Condor Capital Management bought a new position in shares of Phoenix Biotech Acquisition in the 4th quarter worth approximately $64,000. Finally, Yakira Capital Management Inc. bought a new stake in Phoenix Biotech Acquisition during the 4th quarter worth approximately $1,009,000.
NASDAQ PBAXU remained flat at $$10.06 on Thursday. 51 shares of the company’s stock were exchanged, compared to its average volume of 4,652. Phoenix Biotech Acquisition Corp. has a 12 month low of $9.94 and a 12 month high of $11.21. The firm’s 50 day moving average price is $10.08 and its 200-day moving average price is $10.10.
Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAXU)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.